Clinical Trial Update: ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab [Phase 3]

View source ↗

Summary

A Phase III trial (ATALANTE) evaluated atezolizumab versus placebo in late-relapse ovarian cancer patients treated with chemotherapy plus bevacizumab; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Avastin (bevacizumab)
• Tecentriq (atezolizumab)

Snippet

Sponsor: ARCAGY/ GINECO GROUP | Conditions: Ovarian Cancer | Phase 3 | Status: COMPLETED